证券代码：300685 证券简称：艾德生物 公告编号：2025-055 厦门艾德生物医药科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无变更、否决提案的情况； 2.本次股东大会未涉及变更以往股东大会决议； 3.本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 1、召集人：公司董事会 2、召开方式：现场投票与网络投票相结合的方式 3、召开时间： （1）现场会议时间：2025 年 11 月 10 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 10 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2025 年 11 月 10 日 9:15 至 15:00 的任意时间。 4、股权登记日：2025年11月03日 由于公司董事长LI-MOU ZHENG先生因公外出不能主持本次会议，由半数 以上董事共同推举董事阮力先生主持本次会 ...

法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮政编码：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于厦门艾德生物医药科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 上海市锦天城律师事务所 关于厦门艾德生物医药科技股份有限公司 2025年第一次临时股东大会的 按照律师行业公认的业务标准、道德规范和勤勉尽责精神，本所律师对本次 股东会的相关资料和事实进行了核查和验证，现发表法律意见如下： 一、本次股东会的召集、召开程序 1、本次股东会的召集 2025 年 10 月 24 日，公司召开第四届董事会第九次会议，审议通过《关于 召开 2025 年第一次临时股东大会的议案》，决定召开本次股东会。2025 年 10 1 上海市锦天城律师事务所 法律意见书 致：厦门艾德生物医药科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受厦门艾德生物医药科技 股份有限公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年 第一次临时股东大会（以下简称"本次股 ...

新京报讯（记者王卡拉）作为连续八年参展的"全勤生"，阿斯利康在第八届中国国际进口博览会上延续 1000平方米的展台规模，全面展示了其在"推动科学与创新""促进诊疗变革与共同健康""支持可持续发 展"三大举措下的丰硕成果与坚定承诺。本届进博会，阿斯利康举办了30余场活动并宣布多项重磅投资 与合作，带来两款肿瘤创新药的中国首展，再次印证了其依托进博平台，深耕中国、与中国医疗健康产 业同频共振的长期决心。 今年进博会，阿斯利康首次展出了两款最新在华获批用于治疗乳腺癌的肿瘤创新药：荃科得（卡匹色替 片）和达卓优（注射用德达博妥单抗），预计未来五年将惠及16万余名中国乳腺癌患者。阿斯利康旗下 健康科技公司Evinova还与和铂医药达成战略合作，通过深度融合Evinova全球领先的临床试验AI平台与 和铂医药前沿的AI药物研发能力，加速下一代创新药物研发。 阿斯利康在肿瘤领域的探索不仅限于药物创新，更着眼于构建覆盖"筛、诊、治、管"全链路的全病程管 理模式。借助进博会平台，阿斯利康联合临床专家等共同发起前列腺癌早筛公益科普行动，呼吁社会提 升"早筛、早诊、早治"的健康意识，助力前列腺癌防治关口前移。在精准诊断方面，阿斯利 ...

Group 1 - The report highlights a significant increase in the amount of share buybacks and repurchase plans by listed companies, indicating strong market confidence [1][3][9] - In October, the total amount of applications for repurchase and increase loans decreased by 52% month-on-month, primarily due to a 98% drop in increase applications [3][7] - The total amount of applications for special loans reached approximately 153.2 billion, with 63% allocated for repurchases and 37% for increases [6][7] Group 2 - In October, the implementation amount of A-share repurchases decreased, while the planned amount increased by 41% compared to September [9][15] - The top three companies with the largest planned repurchase amounts were Haida Group, COSCO Shipping Holdings, and Jiuan Medical, with amounts of 1-1.6 billion, 750 million-1.5 billion, and 300 million-600 million respectively [9][15] - The A-share controlling shareholders' increase amounts and planned amounts both saw significant month-on-month growth, with completed increases totaling 9.87 billion [15][19] Group 3 - The Hong Kong stock market saw a repurchase amount of approximately 9.37 billion HKD in October, a 55% decrease from September, mainly due to companies entering a quiet period [19][22] - The top three companies in the Hong Kong market for repurchase amounts were Tencent Holdings, HSBC Holdings, and Xiaomi Group-W, with amounts of 3.3 billion HKD, 2.79 billion HKD, and 1.28 billion HKD respectively [19][22] Group 4 - The report identifies companies worth paying attention to for their repurchase and increase announcements, based on their fundamentals, current valuations, and the proportion of repurchase/increase amounts [23][24][25] - Notable A-share companies include Jiuan Medical, Aide Biological, and Zhijiang Biological, with planned repurchase amounts ranging from 60 million to 600 million [24] - In the Hong Kong market, companies like Gushengtang and Lianyi Technology-W are highlighted for their repurchase activities [25]

Core Viewpoint - The overall performance of A-share medical device companies has become clearer as of the end of Q3 2025, with the industry facing continued pressure but showing signs of recovery in the third quarter [1][2]. Financial Performance - As of now, 131 medical device companies have released their Q3 2025 financial data, with total revenue of 179.21 billion yuan, a year-on-year decrease of 2.24%, and a net profit attributable to shareholders of 26.73 billion yuan, down 13.93% year-on-year [2]. - In Q3 2025, the medical device sector saw a revenue increase to 60.39 billion yuan, a year-on-year growth of 2.05%, while net profit decreased by 5.07%, showing a narrowing decline compared to Q2 [2]. - Among the companies, only Mindray Medical achieved over 25.83 billion yuan in revenue for the first nine months, while 50 companies reported net profits exceeding 1 billion yuan [3]. Segment Performance - The performance of different segments within the medical device industry remains divergent, with high-value consumables like orthopedics and electrophysiology showing positive growth due to factors such as technological innovation and international expansion [3][4]. - For instance, Sanyou Medical reported a staggering net profit growth of 623.19% year-on-year, driven by strong sales of its core product, the ultrasonic bone knife [4]. Medical Equipment Sector - The medical equipment sector is experiencing a recovery, with companies like United Imaging achieving a revenue of 8.86 billion yuan in the first three quarters, a year-on-year increase of 27.39% [5]. - Other companies, such as Ribo Instrument, also reported significant growth, with a net profit increase of 118% in Q3 [5][6]. In Vitro Diagnostics (IVD) Sector - The IVD sector continues to face challenges, with only 9 out of 39 companies reporting revenue growth in the first three quarters [7]. - Major players like Mindray Medical and Antu Bio reported declines in revenue, with Mindray's IVD product line experiencing a 2.81% drop in Q3 [8][9]. - New Industries is the only company among the "Five Tigers" to report revenue growth, although its net profit decreased by 12.92% year-on-year [8]. Market Outlook - Despite the current challenges, industry experts believe that the market is beginning to show positive signs, with the most difficult period likely behind [9]. - Companies with core technological advantages and strong international presence are expected to recover more quickly as the market stabilizes [9].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300685 证券简称：艾德生物 公告编号：2025-054 厦门艾德生物医药科技股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东 持股情况的公告 | 序号 | 账户名称 | 持股数量 （股） | 占无限售条件 流通股股本比 | | --- | --- | --- | --- | | | | | 例（%） | | 1 | 前瞻投资（香港）有限公司 | 87,701,616 | 22.51 | | 2 | 香港中央结算有限公司 | 31,394,756 | 8.06 | | 3 | 厦门科英投资合伙企业（有限合伙） | 15,940,946 | 4.09 | | 4 | 宁波屹祥自有资金投资合伙企业（有限合伙） | 8,731,000 | 2.24 | | 5 | 中国银行股份有限公司－华宝中证医疗交易型开放式 指数证券投资基金 | 7,964,200 | 2.04 | | 6 | 厦门市海沧区润鼎盛投资合伙企业（普通合伙） | 4,098,726 | 1.05 | | 7 | 宋宁 | 3 ...

Market Overview - US stock market showed mixed results with the Nasdaq and S&P 500 indices closing higher, driven primarily by AI-related trades [1] - The Dow Jones Industrial Average fell by 226.19 points, a decrease of 0.48%, closing at 47,336.68 points [1] - The Nasdaq rose by 0.46%, closing at 23,834.72 points, while the S&P 500 increased by 0.17%, closing at 6,851.97 points [1] Cryptocurrency Market - The cryptocurrency market experienced a significant drop, with Bitcoin falling over 3% and Ethereum declining more than 6% [1] - The decline was triggered by a hacker attack on the decentralized finance protocol Balancer, resulting in potential losses exceeding $100 million [1] Semiconductor Sector - The Philadelphia Semiconductor Index rose nearly 1%, buoyed by a long-term $9.7 billion agreement between IREN and Microsoft for the use of Nvidia's GB300 GPU [2] - IREN's stock surged over 10%, while Micorosft's stock dipped by 0.2% [2] - Micron Technology saw a nearly 5% increase, leading the chip sector, and Nvidia's stock rose over 2% [2] Major Tech Companies - Amazon's stock increased by 4.0%, reaching a new all-time high after announcing a $38 billion agreement with OpenAI to run and expand its AI operations on Amazon Web Services (AWS) [2] - Other notable tech stocks included Microsoft down 0.1%, Google up 0.8%, Apple down 0.5%, Meta down 1.6%, and Oracle down 1.8% [3] Earnings Reports - The earnings season continues with major companies like AMD, Shopify, McDonald's, Uber Technologies, Pfizer, Spotify, and Warner Bros. Discovery set to release their quarterly financial reports later this week [3] Economic Data - The US manufacturing index for October fell to 48.7 from 49.1 in September, below the market expectation of 49.5 [3] - The S&P Global US manufacturing index was revised up to 52.5 from an initial estimate of 52.2, showing improvement from September's 52.0 [3] Federal Reserve Insights - The ISM price index showed a decline last month, providing more grounds for the Federal Reserve to consider another rate cut [4] - The market currently anticipates a 65% probability of a 25 basis point rate cut next month [5] - Federal Reserve officials expressed differing views on further rate cuts, with some advocating for more easing while others remain cautious due to high inflation [5] Bond and Commodity Markets - US Treasury yields showed mixed performance, with the 10-year yield rising by 1 basis point to 4.11% and the 2-year yield falling by 1 basis point to 3.60% [6] - International oil prices experienced slight fluctuations, with WTI crude oil near $64.05 per barrel and Brent crude at $64.89 per barrel [6] - Gold prices saw a minor rebound, with COMEX gold futures for November delivery rising by 0.45% to $4,000.30 per ounce [7] Corporate Developments - Kimberly-Clark's stock plummeted by 15% following news of a potential acquisition of Kenvue, the producer of Tylenol, for over $40 billion [3] - Starbucks announced plans to sell a majority stake in its China business to private equity firm Boyu Capital for $4 billion, retaining a 40% stake [15] - TSMC plans to implement a price increase of approximately 3%-5% for advanced processes below 5nm starting January 2026 [16]

Policy Developments - The National Health Commission and five other departments launched a one-year special campaign against illegal ambulances, targeting both registered "ambulance" vehicles and unregistered "black ambulances" [2] - The campaign includes comprehensive inspections, management principles, and encourages social participation in medical transport services [2][3] Drug and Medical Device Approvals - Aied Bio received a medical device registration certificate for its gene mutation detection kit, which is now approved in China, Japan, and Europe, aiding non-small cell lung cancer patients [4] - Hainan Haiyao's subsidiary obtained a drug registration certificate for Fumaric Acid Vonoprazan Tablets, the first P-CAB for reflux esophagitis in China [5] Capital Market Activities - China National Pharmaceutical Modern signed a drug listing license transfer contract for Lactulose Oral Solution, with a total transfer fee of 5.86 million yuan, projected to generate 2.069 billion yuan in sales in 2024 [6] - Jiangsu Hengrui Medicine and Neurocrine Biosciences entered a collaboration for developing NLRP3 inhibitors, with a potential total value of $881.5 million [7][8] Industry Events - The 2025 medical insurance negotiation concluded, with results expected to be announced in early December [9] - The only approved stem cell drug in China, Aimi Maito Sai Injection, is included in the "Beijing Universal Health Insurance" with a maximum reimbursement of 65% [10] Regulatory Issues - The executive director of CSPC Pharmaceutical Group was fined 5 million yuan for insider trading related to a merger announcement [11]

Group 1 - The Ministry of Finance's Debt Management Department has been included in the "Ministry Organization" list, with responsibilities including formulating and executing domestic debt management policies and monitoring government debt risks [2] - China Mobile announced the transfer of 41,981,300 shares to China National Petroleum Corporation, following a previous transfer of 541 million shares from China National Petroleum to China Mobile [2] - Hangzhou Yundeshuchu Technology Co., Ltd. has changed its name to Hangzhou Yundeshuchu Technology Co., Ltd. and has completed its share reform, transitioning from a limited liability company to a non-listed joint-stock company [2] Group 2 - As of November 3, Hong Kong's IPO financing reached HKD 216.474 billion, a year-on-year increase of 203.5%, with 81 companies listed, up 50% year-on-year [2] - The A-share market showed a positive trend on November 3, with the Shanghai Composite Index rising by 0.55%, and significant gains in major oil stocks, particularly China National Petroleum, which rose by 4.48% [4] - The report indicates that the A-share market is expected to maintain a slow upward trend due to favorable policies and the onset of a Federal Reserve rate cut cycle [4][5] Group 3 - The price of memory chips has continued to rise, with DDR5 16G, DDR4 16Gb, and DDR3 4Gb prices increasing by 0.48%, 2.41%, and 0.3% respectively [7] - Major manufacturers like Samsung and SK Hynix have announced significant price increases for DRAM and NAND flash memory, driven by surging demand from AI applications [7] - The implementation of a high-quality development plan for water-saving equipment aims to enhance the competitiveness of the industry and promote sustainable economic development [8] Group 4 - Strong瑞技术 plans to invest CNY 70 million in Dongguan Aluminum Treasure Metal Technology Co., Ltd., acquiring a 35% stake, focusing on AI server and electronic vehicle applications [9] -迈克生物 has received medical device registration certificates for several products, enhancing its market presence in the diagnostics sector [10] -阿特斯 has signed supply and long-term service agreements for battery storage projects in Ontario, Canada, with a total capacity of 420 MW [13]

Investment Rating - The investment rating has been downgraded to "Outperform" [1][4] Core Insights - The company reported a revenue of RMB 1.58 billion for the first nine months of 2025, a 4.05% increase from RMB 1.52 billion in the same period of 2024. Q3 2025 revenue was RMB 541 million, up 3.47% year-on-year. However, net profit for the same period was RMB 116 million, down 17.34% year-on-year, with a net profit margin of 7.31%. Q3 2025 net profit was RMB 34 million, down 40.90% year-on-year. The forecasted EPS for 2025-2027 is RMB 0.44, 0.50, and 0.60 respectively, with a target price of RMB 15.36 based on a PE of 35X for 2025. The downgrade is attributed to the anticipated slow growth in gene sequencing services [4][11][12]. Financial Summary - Total revenue projections are as follows: - 2023A: RMB 2,002 million - 2024A: RMB 2,111 million - 2025E: RMB 2,197 million - 2026E: RMB 2,441 million - 2027E: RMB 2,716 million - Net profit (attributable to the parent) is projected as: - 2023A: RMB 178 million - 2024A: RMB 197 million - 2025E: RMB 183 million - 2026E: RMB 210 million - 2027E: RMB 249 million - The net profit margin is expected to fluctuate, with a decrease in 2025E [3][6][11]. R&D and Strategic Investments - The company has maintained high R&D investment, with R&D expenses reaching RMB 119 million from January to September 2025, a 50.48% increase year-on-year, accounting for 7.51% of revenue. Q3 2025 R&D expenses were RMB 56.10 million, focusing on emerging fields such as single-cell, spatial omics, and proteomics [12][13]. - The company is also investing in global expansion and customer engagement, which has led to increased R&D expenses and fluctuations in gross profit margin [12][14]. Sales and Marketing Expenses - Sales expenses have slightly increased due to global localization and marketing upgrades, with a sales expense ratio of 20.38% from January to September 2025, up 0.76 percentage points year-on-year. The Q3 2025 sales expense ratio was 21.06%, up 1.43 percentage points year-on-year [14].